Neurocrine Biosciences, Inc.
NBIX
Κατάταξη σε μετοχές
#1514
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the... Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
Τιμή μετοχής
$141.77
Τελευταίος συγχρονισμός: 2026-10-20
Κεφαλαιοποίηση
$14.41B
Αλλαγή (1 ημέρα)
3.49%
Αλλαγή (1 έτος)
-0.62%
Χώρα
US
Εμπόριο Neurocrine Biosciences, Inc. (NBIX)
Κατηγορία
Healthcare
Έσοδα για την Neurocrine Biosciences, Inc. (NBIX)
Έσοδα τον Jun 2026 TTM: $3.37B
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Neurocrine Biosciences, Inc., τα τρέχοντα έσοδα της εταιρείας (TTM) είναι $3.37B. Το 2024, η εταιρεία είχε έσοδα $2.36B αύξηση σε σχέση με τα έσοδα του έτους 2023, τα οποία ήταν $1.89B. Τα έσοδα είναι το συνολικό ποσό που παράγει μια εταιρεία από τις πωλήσεις προϊόντων ή υπηρεσιών. Σε αντίθεση με τα κέρδη, δεν αφαιρούνται έξοδα.
Ιστορικό εσόδων για την Neurocrine Biosciences, Inc. από 2000 έως 2026
Έσοδα στο τέλος κάθε έτους
| Έτος | Έσοδα | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $3.37B | 17.95% |
| 2025 | $2.86B | 21.45% |
| 2024 | $2.36B | 24.81% |
| 2023 | $1.89B | 26.76% |
| 2022 | $1.49B | 31.34% |
| 2021 | $1.13B | 8.38% |
| 2020 | $1.05B | 32.71% |
| 2019 | $788.10M | 74.67% |
| 2018 | $451.20M | 179.16% |
| 2017 | $161.63M | 977.51% |
| 2016 | $15.00M | -24.12% |
| 2015 | $19.77M | 0.00% |
| 2014 | 0.00 | -100.00% |
| 2013 | $2.92M | -94.51% |
| 2012 | $53.14M | -31.36% |
| 2011 | $77.41M | 131.08% |
| 2010 | $33.50M | 1,034.47% |
| 2009 | $2.95M | -25.71% |
| 2008 | $3.98M | 224.75% |
| 2007 | $1.22M | -96.88% |
| 2006 | $39.23M | -68.33% |
| 2005 | $123.89M | 45.45% |
| 2004 | $85.18M | -38.76% |
| 2003 | $139.08M | 670.73% |
| 2002 | $18.05M | -56.25% |
| 2001 | $41.24M | 182.71% |
| 2000 | $14.59M | 0.00% |
Έσοδα για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Έσοδα | Διαφορά Εσόδων | Χώρα |
|---|---|---|---|
| $12.62B | 274.18% |
US
|
|
| $2.23B | -33.96% |
US
|
|
| $15.74B | 366.65% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 78.47% |
NL
|
